Werner Neidhart

TL;DR: Bosentan is the most potent orally active antagonist of ET receptors described so far and its pharmacological profile makes bosentan a potentially useful drug in the management of clinical disorders associated with vasoconstriction.

TL;DR: A chemically advanced template search based on topological pharmacophore models has been developed as a technique for virtual screening and has successfully identified novel potent Ca(2+) antagonists in a library of several hundred thousand compounds on the basis of a correlation vector representation.

TL;DR: Evidence is reported here for the pathophysiological role of endothelin-1 as brought by the first synthetic orally active non-peptide antagonist ofendothelin receptors, Ro 46-2005.

TL;DR: A computer-based method was developed for rapid and automatic identification of potential "frequent hitters" that will be a valuable tool for the prioritization of compounds from large databases, for compound purchase and biological testing, and for building new virtual libraries.

TL;DR: It is demonstrated that Ro 61-1790 is a potent and selective ETA receptor antagonist suitable for parenteral use and potentially useful for preventing delayed ischemic deficit in patients with SAH.